Cornea

Investigators examine usefulness in refractive surgery evaluations.

CXL is safe, effective to perform on younger population, study results show.

Researchers believe the vial has the potential to transform the way corneal grafts are preserved and will provide scientists with a platform to develop customized preservation solutions.

Investigators examine usefulness in refractive surgery evaluations

Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.

A survey by Health Union sheds light on the issues patients are facing and can help ophthalmologists map out dry eye disease treatment strategies.

CAM’s regenerative healing means long-term relief and fewer visits to clinic.

Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.

Tool for quantifying measures may predict outcomes for patients.

According to Oculus, its Myopia Master saves space and can be mounted on a workstation or an ophthalmic table. The software is operated directly via an inbuilt display.

The company is evaluating topical cyclosporine to treat the signs and symptoms of dry eye disease.

According to the Refractive Surgery Council, patients continue to have a high level of interest in laser vision correction procedures.

Most patients with allergic disorder are children, adolescents, or young adults.

Edward Manche, MD, discusses results from his presentation regarding outcomes of corneal crosslinking keratoconus in a pediatric population.

Trifocal IOLs can, if implanted with caution, be suitable for patients with keratoconus.

A team of investigators used corneal confocal microscopy to identify corneal nerve damage in cases of long COVID.

Steven Greenstein, MD, reports on results of epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients 10 years after undergoing laser refractive surgery.

Kathryn M. Hatch, MD, details how collagen CXL is evolving with the goals of reducing complications and actually improving visual acuity.

Ex vivo experiment identifies potential benefit for supplementary oxygen.

Cynthia Matossian, MD, FACS, provides an overview on dry eye flares, including causes, symptoms, and her experience with dry eye flare patients.

Santen Inc. announced Thursday that the U.S. FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops to treat vernal keratoconjunctivitis (VKC).

Patients who are members of racial and ethnic minority groups present clinically with worse objective measures of dry eye than patients who do not belong to these groups, new research shows.

According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.

Postop management with long-term topical antibiotics is critical to successful device retention.

Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).